GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mendus AB (CHIX:IMMUs) » Definitions » Notes Receivable

Mendus AB (CHIX:IMMUS) Notes Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mendus AB Notes Receivable?

Mendus AB's Notes Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Mendus AB Notes Receivable Historical Data

The historical data trend for Mendus AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mendus AB Notes Receivable Chart

Mendus AB Annual Data
Trend Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mendus AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mendus AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Mendus AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Mendus AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mendus AB (CHIX:IMMUS) Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company that focuses on the development of immunotherapies that address tumor recurrence and difficult-to-treat established tumors. Its operations consist of research and development for pharmaceuticals.

Mendus AB (CHIX:IMMUS) Headlines

No Headlines